En esta página
EWTX Edgewise Therapeutics, Inc. - Common Stock
NASDAQ · Pharmaceuticals · Ver en SEC EDGAR ↗ cerrar Oct 2, 2026 10-K/10-Q Ago 6, 2026
$41,40
· % del rango de 52 semanas
· por encima del mínimo
· a alto
$14,25mínimo 52 semanas
$48,51máximo 52 semanas
Capitalización Bursátil (MRQ)
$4.46B
P/E
-25.7
BPA
$-1.63
tus insignias
Rango 52S
$14–$49
Calificación del Analista
BUY
Precio Objetivo
$53
P/E
-25.7
ROE
-30.2%
Margen de Beneficio Neto
·
Tu barra de insignias está vacía — fija una métrica en cualquier lugar de esta página.
EWTX Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$41.40
Capitalización Bursátil (MRQ)
$4.46B
P/E
-25.7
BPA
$-1.63
ROE
-30.2%
Rango 52S
$14–$49
EWTX Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
rango
barras
La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
BPA$-1.632020-12-31 → 2025-12-31
Flujo de caja libre$-144M2021-12-31 → 2025-12-31
Valoración y ratios
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
| Métrica | Tendencia a 5 años | EWTX | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| P/E | -25.7promedio 5A ≈-12.2 | ≈-12.2 | · | · | |
| P/C (MRQ) | 10.0promedio 5A ≈3.5 | ≈3.5 | 6.5 | Sobrevalorado | |
| Precio / FCF (TTM) | -28.1promedio 5A ≈-16.2 | ≈-16.2 | · | · | |
| Precio / Flujo de Caja (TTM) | -28.2promedio 5A ≈-16.7 | ≈-16.7 | · | · | |
| Price / Tangible Book (Precio / Valor Contable Tangible) | 8.5promedio 5A ≈3.5 | ≈3.5 | · | · |
La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
| Métrica | Tendencia a 5 años | EWTX | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| ROA | -32.3%promedio 5A ≈-26.9% | ≈-26.9% | -20.0% | Débil | |
| ROE | -30.2%promedio 5A ≈-25.1% | ≈-25.1% | -20.8% | Débil | |
| ROIC | -36.6% | · | -17.6% | Débil |
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
| Métrica | Tendencia a 5 años | EWTX | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Ratio corriente (MRQ) | 16.2promedio 5A ≈21.6 | ≈21.6 | 11.6 | Liquidez sólida | |
| Quick Ratio (Ratio Rápido) | 2.2promedio 5A ≈2.4 | ≈2.4 | 5.0 | Baja liquidez |
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Aún no hay datos para este grupo de ratios
Aún no hay datos fundamentales para este ticker.
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Aún no hay datos para este grupo de ratios
Aún no hay datos fundamentales para este ticker.
valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
2.7%
Próximo informe
Nov 04, 2026
| Período | Informe | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|---|
| 30 de junio de 2026 | Ago 6, 2026 | $-0.53 | $-0.48 | -10.6% |
| 31 de marzo de 2026 | May 7, 2026 | $-0.46 | $-0.50 | 7.3% |
| 31 de diciembre de 2025 | $-0.47 | $-0.44 | -5.7% | |
| 30 de septiembre de 2025 | $-0.39 | $-0.41 | 3.8% | |
| 30 de junio de 2025 | $-0.34 | $-0.42 | 19.8% | |
| 31 de marzo de 2025 | $-0.43 | $-0.44 | 1.7% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $151M | $127M | $91M | $54M | $32M | $15M | |
| SG&A Expense | $40M | $32M | $23M | $18M | $11M | $2M | |
| Operating Expenses | $191M | $159M | $114M | $72M | $43M | $17M | |
| Operating Income | $-191M | $-159M | $-114M | $-72M | $-43M | $-17M | |
| Pretax Income | $-168M | $-134M | $-100M | · | · | · | |
| Income Tax | $4.0K | $3.0K | $4.0K | $0 | $0 | · | |
| Net Income | $-168M | $-134M | $-100M | $-68M | $-43M | $-17M | |
| EPS (Basic) | $-1.63 | $-1.45 | $-1.57 | $-1.26 | $-1.14 | $-23.17 | |
| EPS (Diluted) | $-1.63 | $-1.45 | $-1.57 | $-1.26 | $-1.14 | $-23.17 | |
| Shares (Basic) | 102,930,744 | 92,414,626 | 63,723,600 | 53,593,753 | 37,526,332 | 739,004 | |
| Shares (Diluted) | 102,930,744 | 92,414,626 | 63,723,600 | 53,593,753 | 37,526,332 | 739,004 | |
| EBITDA | $-191M | $-159M | $-114M | $-72M | $-43M | · |
Balance general
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $61M | $42M | $86M | $22M | $16M | $105M | |
| Prepaid Expense | $13M | $5M | $9M | $5M | $3M | $551.0K | |
| Current Assets | $543M | $475M | $327M | $357M | $284M | $130M | |
| PP&E (Net) | $8M | $10M | $10M | $9M | $912.0K | $516.0K | |
| PP&E (Gross) | $15M | $14M | $13M | $10M | $2M | $946.0K | |
| Accum. Depreciation | $7M | $5M | $3M | $1M | $702.0K | $430.0K | |
| Other Non-current Assets | · | $262.0K | $348.0K | $251.0K | $548.0K | $975.0K | |
| Total Assets | $553M | $487M | $340M | $367M | $285M | $131M | |
| Accounts Payable | $6M | $6M | $4M | $6M | $4M | $2M | |
| Accrued Liabilities | $8M | $7M | $6M | $6M | $4M | $2M | |
| Current Liabilities | $27M | $24M | $17M | $17M | $11M | $4M | |
| Capital Leases | $3M | $4M | $4M | $4M | · | · | |
| Other Non-current Liabilities | · | · | · | · | $329.0K | · | |
| Total Liabilities | $30M | $28M | $21M | $20M | $11M | $4M | |
| Common Stock | $10.0K | $9.0K | $7.0K | $6.0K | $5.0K | · | |
| Paid-in Capital | $1.07B | $837M | $563M | $493M | $352M | $727.0K | |
| Retained Earnings | $-546M | $-379M | $-245M | $-145M | $-77M | $-34M | |
| AOCI | $677.0K | $420.0K | $99.0K | $-1M | $-514.0K | · | |
| Stockholders' Equity | $522M | $459M | $319M | $347M | $274M | $-33M | |
| Liabilities + Equity | $553M | $487M | $340M | $367M | $285M | $131M | |
| Shares Outstanding | 106,249,579 | 94,838,466 | 70,453,342 | 63,257,376 | 49,500,308 | 1,009,479 |
Flujo de Efectivo
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Stock-based Comp | $35M | $25M | $18M | $11M | $4M | $354.0K | |
| Operating Cash Flow | $-144M | $-109M | $-92M | $-53M | $-34M | $-15M | |
| CapEx | $256.0K | $1M | $6M | $6M | $668.0K | $203.0K | |
| Investing Cash Flow | $-33M | $-185M | $103M | $-71M | $-242M | $-24M | |
| Stock Issued | $187M | $239M | $53M | $129M | · | · | |
| Net Stock Activity | $187M | $239M | $53M | $129M | · | · | |
| Financing Cash Flow | $196M | $249M | $53M | $130M | $186M | $120M | |
| Net Change in Cash | $19M | $-44M | $64M | $6M | $-89M | $81M | |
| Free Cash Flow | $-144M | $-110M | $-98M | $-58M | $-34M | · |
Rentabilidad
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| ROA | -32.3% | -32.4% | -28.3% | -20.7% | -20.6% | · | |
| ROE | -30.2% | -28.2% | -32.9% | -19.1% | -15.3% | · | |
| ROIC | -36.6% | · | · | · | · | · |
Liquidez y Solvencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 19.9 | 19.9 | 19.5 | 21.5 | 27.0 | · | |
| Quick Ratio | 2.2 | 1.7 | 5.1 | 1.3 | 1.5 | · |
Por Acción
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $4.92 | $4.84 | $4.53 | $5.48 | $5.54 | · | |
| Cash Flow / Share | $-1.40 | $-1.18 | $-1.44 | $-0.98 | $-0.89 | · | |
| Cash / Share | $0.58 | $0.44 | $1.22 | $0.35 | $0.31 | · | |
| EPS (TTM) | $-1.63 | $-1.45 | $-1.57 | $-1.26 | $-1.14 | · |
Valoración (TTM)
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Net Income TTM | $-168M | $-134M | $-100M | $-68M | $-43M | · | |
| Market Cap | $2.64B | $2.53B | $771M | $566M | $756M | · | |
| P/E | -15.2 | -18.4 | -7.0 | -7.1 | -13.4 | · | |
| P/B | 5.0 | 5.5 | 2.4 | 1.6 | 2.8 | · | |
| P / Tangible Book | 5.0 | 5.5 | 2.4 | 1.6 | 2.8 | · | |
| P / Cash Flow | -18.3 | -23.2 | -8.4 | -10.7 | -22.6 | · | |
| P / FCF | -18.3 | -22.9 | -7.9 | -9.7 | -22.1 | · | |
| Earnings Yield | -6.6% | -5.4% | -14.3% | -14.1% | -7.5% | · |
Estado de resultados
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $48M | $43M | $44M | $37M | $34M | $37M | $36M | $32M | $31M | $28M | $24M | $20M | $20M | $17M | $14M | $12M | |
| SG&A Expense | $14M | $11M | $12M | $9M | $9M | $9M | $9M | $8M | $7M | $7M | $6M | $6M | $6M | $5M | $4M | $4M | |
| Operating Expenses | $62M | $54M | $56M | $47M | $43M | $46M | $46M | $40M | $38M | $35M | $29M | $25M | $26M | $22M | $18M | $16M | |
| Operating Income | $-62M | $-54M | $-56M | $-47M | $-43M | $-46M | $-46M | $-40M | $-38M | $-35M | $-29M | $-25M | $-26M | $-22M | $-18M | $-16M | |
| Net Income | $-57M | $-49M | $-50M | $-41M | $-36M | $-41M | $-40M | $-34M | $-31M | $-29M | $-26M | $-21M | $-23M | $-19M | $-17M | $-16M | |
| EPS (Basic) | $-0.53 | $-0.46 | $-0.47 | $-0.39 | $-0.34 | $-0.43 | $-0.42 | $-0.36 | $-0.34 | $-0.33 | $-0.41 | $-0.34 | $-0.36 | $-0.30 | $-0.34 | $-0.32 | |
| EPS (Diluted) | $-0.53 | $-0.46 | $-0.47 | $-0.39 | $-0.34 | $-0.43 | $-0.42 | $-0.36 | $-0.34 | $-0.33 | $-0.41 | $-0.34 | $-0.36 | $-0.30 | $-0.34 | $-0.32 | |
| Shares (Basic) | 107,669,774 | 107,116,709 | · | 105,492,779 | 104,940,493 | 95,130,053 | · | 93,813,346 | 93,515,356 | 87,567,307 | 63,459,560 | 63,380,430 | 63,265,800 | · | 51,844,904 | 49,622,752 | |
| Shares (Diluted) | 107,669,774 | 107,116,709 | · | 105,492,779 | 104,940,493 | 95,130,053 | · | 93,813,346 | 93,515,356 | 87,567,307 | 63,459,560 | 63,380,430 | 63,265,800 | · | 51,844,904 | 49,622,752 | |
| EBITDA | $-62M | $-54M | · | $-47M | $-43M | $-46M | · | $-40M | $-38M | $-35M | $-29M | $-25M | $-26M | · | $-18M | $-16M |
Balance general
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $72M | $33M | $61M | $46M | $43M | $50M | $42M | $45M | $43M | $30M | $33M | $32M | $48M | $22M | $110M | $18M | |
| Prepaid Expense | $6M | $10M | $13M | $11M | $9M | $7M | $5M | $7M | $8M | $9M | $8M | $7M | $5M | $5M | $5M | $5M | |
| Current Assets | $472M | $510M | $543M | $574M | $603M | $443M | $475M | $499M | $519M | $541M | $298M | $317M | $333M | $357M | $370M | $253M | |
| PP&E (Net) | $7M | $7M | $8M | $8M | $9M | $9M | $10M | $10M | $10M | $10M | $11M | $11M | $10M | $9M | $5M | $2M | |
| PP&E (Gross) | $15M | $15M | $15M | $14M | $14M | $14M | $14M | $14M | $13M | $13M | $13M | $13M | $12M | $10M | $6M | $3M | |
| Accum. Depreciation | $8M | $7M | $7M | $6M | $6M | $5M | $5M | $4M | $4M | $3M | $2M | $2M | $1M | $1M | $977.0K | $882.0K | |
| Other Non-current Assets | · | · | · | · | · | $695.0K | $262.0K | $262.0K | $262.0K | · | $467.0K | $419.0K | $251.0K | $251.0K | $264.0K | $447.0K | |
| Total Assets | $480M | $519M | $553M | $583M | $613M | $454M | $487M | $511M | $532M | $554M | $311M | $331M | $346M | $367M | $377M | $257M | |
| Accounts Payable | $5M | $7M | $6M | $6M | $8M | $9M | $6M | $6M | $7M | $5M | $5M | $4M | $4M | $6M | $6M | $3M | |
| Accrued Liabilities | $5M | $9M | $8M | $6M | $6M | $7M | $7M | $6M | $5M | $6M | $6M | $7M | $6M | $6M | $5M | $4M | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $7.0K | · | |
| Current Liabilities | $29M | $23M | $27M | $22M | $21M | $21M | $24M | $19M | $17M | $15M | $16M | $14M | $13M | $17M | $13M | $9M | |
| Capital Leases | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $3M | $4M | $4M | $5M | $5M | $5M | $4M | $2M | $2M | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $192.0K | |
| Total Liabilities | $32M | $25M | $30M | $25M | $24M | $25M | $28M | $22M | $21M | $19M | $21M | $19M | $18M | $20M | $16M | $11M | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $59.0K | · | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $7.0K | · | |
| Common Stock | $10.0K | $10.0K | $10.0K | $10.0K | $10.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $5.0K | |
| Paid-in Capital | $1.10B | $1.09B | $1.07B | $1.05B | $1.04B | $849M | $837M | $827M | $816M | $809M | $505M | $501M | $497M | $493M | $489M | $356M | |
| Retained Earnings | $-653M | $-595M | $-546M | $-496M | $-455M | $-419M | $-379M | $-339M | $-305M | $-273M | $-215M | $-189M | $-167M | $-145M | $-125M | $-108M | |
| AOCI | $-500.0K | $-252.0K | $677.0K | $701.0K | $204.0K | $401.0K | $420.0K | $1M | $-1M | $-861.0K | $-424.0K | $-547.0K | $-251.0K | $-1M | $-2M | $-2M | |
| Stockholders' Equity | $448M | $493M | $522M | $559M | $589M | $430M | $459M | $489M | $510M | $535M | $290M | $311M | $329M | $347M | $361M | $246M | |
| Liabilities + Equity | $480M | $519M | $553M | $583M | $613M | $454M | $487M | $511M | $532M | $554M | $311M | $331M | $346M | $367M | $377M | $257M | |
| Shares Outstanding | 107,776,380 | 107,481,522 | 106,249,579 | 105,761,949 | 105,341,296 | 95,205,683 | 94,838,466 | 94,408,911 | 93,643,341 | 93,284,528 | 63,460,939 | 63,458,932 | 63,274,732 | 63,257,376 | 63,208,828 | 49,780,365 |
Flujo de Efectivo
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $9M | $9M | $10M | $8M | $8M | $9M | $8M | $7M | $5M | $5M | $5M | $4M | $4M | $4M | $3M | $2M | |
| Operating Cash Flow | $-42M | $-43M | $-39M | $-35M | $-33M | $-38M | $-27M | $-27M | $-26M | $-29M | $-22M | $-20M | $-23M | $-12M | $-12M | $-16M | |
| CapEx | $32.0K | $260.0K | $73.0K | $89.0K | $50.0K | $44.0K | $274.0K | $520.0K | $221.0K | $297.0K | $457.0K | $759.0K | $4M | $3M | $1M | $554.0K | |
| Investing Cash Flow | $78M | $2M | $50M | $36M | $-162M | $44M | $21M | $25M | $37M | $-268M | $23M | $3M | $49M | $-76M | $-26M | $-46.0K | |
| Stock Issued | · | · | $0 | $0 | · | · | $0 | $0 | $0 | $239M | · | · | · | $-555.0K | · | · | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $239M | · | · | · | · | · | · | |
| Financing Cash Flow | $3M | $12M | $4M | $2M | $188M | $2M | $3M | $3M | $2M | $241M | $-211.0K | $369.0K | $21.0K | $-303.0K | $130M | $179.0K | |
| Net Change in Cash | $39M | $-28M | $15M | $3M | $-7M | $8M | $-3M | $1M | $13M | $-56M | $1M | $-16M | $26M | $-88M | $91M | $-16M | |
| Free Cash Flow | · | $-43M | · | · | · | · | · | · | · | $-29M | · | · | $-27M | · | · | · |
Rentabilidad
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -10.5% | -10.1% | · | -7.4% | -6.3% | -8.1% | · | -8.3% | -7.3% | -6.3% | -7.5% | -7.3% | -7.4% | · | -5.2% | -5.7% | |
| ROE | -11.1% | -10.6% | · | -7.8% | -6.6% | -8.5% | · | -8.8% | -7.7% | -6.6% | -7.9% | -7.7% | -7.8% | · | -5.4% | -5.9% |
Liquidez y Solvencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 16.2 | 22.6 | · | 26.5 | 28.9 | 21.0 | · | 26.3 | 30.2 | 37.1 | 18.2 | 22.0 | 26.2 | · | 27.8 | 27.5 | |
| Quick Ratio | 2.5 | 1.5 | · | 2.1 | 2.1 | 2.4 | · | 2.4 | 2.5 | 2.1 | 2.0 | 2.2 | 3.8 | · | 8.2 | 2.0 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 | · |
Por Acción
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $4.16 | $4.59 | · | $5.28 | $5.59 | $4.51 | · | $5.18 | $5.45 | $5.73 | $4.58 | $4.91 | $5.20 | · | $5.72 | $4.95 | |
| Cash Flow / Share | · | $-0.40 | · | · | · | $-0.40 | · | · | · | $-0.33 | · | · | $-0.36 | · | · | · | |
| Cash / Share | $0.67 | $0.31 | · | $0.43 | $0.41 | $0.52 | · | $0.47 | $0.46 | $0.32 | $0.52 | $0.50 | $0.76 | · | $1.74 | $0.37 | |
| EPS (TTM) | $-1.85 | $-1.66 | · | $-1.58 | $-1.55 | $-1.55 | · | $-1.49 | $-1.54 | $-1.54 | $-1.41 | $-1.34 | $-1.32 | · | $2.74 | $2.82 |
Valoración (TTM)
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-197M | $-176M | · | $-157M | $-151M | $-146M | · | $-124M | $-116M | $-106M | $-89M | $-81M | $-76M | · | $-61M | $-56M | |
| Market Cap | $4.38B | $3.39B | · | $1.72B | $1.38B | $2.09B | · | $2.52B | $1.69B | $1.70B | $364M | $492M | $422M | · | $622M | $396M | |
| Enterprise Value | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $512M | · | |
| P/E | -22.0 | -19.0 | · | -10.3 | -8.5 | -14.2 | · | -17.9 | -11.7 | -11.8 | -4.1 | -5.8 | -5.1 | · | 3.6 | 2.8 | |
| P/B | 9.8 | 6.9 | · | 3.1 | 2.3 | 4.9 | · | 5.2 | 3.3 | 3.2 | 1.3 | 1.6 | 1.3 | · | 1.7 | 1.6 | |
| P / Tangible Book | 9.8 | 6.9 | · | 3.1 | 2.3 | 4.9 | · | 5.2 | 3.3 | 3.2 | 1.3 | 1.6 | 1.3 | · | 1.7 | 1.6 | |
| P / Cash Flow | · | -79.6 | · | · | · | -55.3 | · | · | · | -59.5 | · | · | -18.5 | · | · | · | |
| Earnings Yield | -4.5% | -5.3% | · | -9.7% | -11.8% | -7.0% | · | -5.6% | -8.6% | -8.4% | -24.6% | -17.3% | -19.8% | · | 27.9% | 35.4% |
Período más reciente a la izquierda · valores nulos mostrados como ·
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Beneficio neto | $-168M | $-134M | $-100M | $-68M | $-43M |
| EPS Diluido | $-1.63 | $-1.45 | $-1.57 | $-1.26 | $-1.14 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ratio corriente | 19.9 | 19.9 | 19.5 | 21.5 | 27.0 |
| Ratio Rápido | 2.2 | 1.7 | 5.1 | 1.3 | 1.5 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flujo de caja libre | $-144M | $-110M | $-98M | $-58M | $-34M |
Propietarios institucionales (13F) 247 declarantes · $4.9B total · A fecha de 30 de septiembre de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Tenedores
247
Valor en tenencia
$4.9B
Nuevas posiciones
41
Posiciones cerradas
25
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 41 (-11 vs trimestre anterior) | 25 (+2 vs trimestre anterior) | 85 (+18 vs trimestre anterior) | 76 (+8 vs trimestre anterior) | -5.6M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | $630 516 330 | 15 518 492 | 12,91% | Acciones |
| Paradigm Biocapital Advisors LP | $415 053 937 | 10 215 455 | 8,50% | Acciones |
| RA CAPITAL MANAGEMENT, L.P. | $340 996 620 | 8 392 730 | 6,98% | Acciones |
| BlackRock, Inc. | $268 415 431 | 6 606 336 | 5,50% | Acciones |
| FMR LLC | $223 023 556 | 5 489 135 | 4,57% | Acciones |
| NOVO HOLDINGS A/S | $217 370 500 | 5 350 000 | 4,45% | Acciones |
| Driehaus Capital Management LLC | $192 123 952 | 4 728 623 | 3,94% | Acciones |
| JANUS HENDERSON GROUP PLC | $186 289 082 | 5 915 556 | 3,82% | Acciones |
| PERCEPTIVE ADVISORS LLC | $177 714 564 | 4 373 974 | 3,64% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $156 859 022 | 3 860 670 | 3,21% | Acciones |
| BAKER BROS. ADVISORS LP | $150 400 843 | 3 701 719 | 3,08% | Acciones |
| Siren, L.L.C. | $129 391 476 | 3 184 629 | 2,65% | Acciones |
| VANGUARD GROUP INC | $120 889 349 | 4 871 624 | 2,48% | Acciones |
| Cormorant Asset Management, LP | $101 981 300 | 2 510 000 | 2,09% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $88 348 054 | 2 174 051 | 1,81% | Acciones |
| Integral Health Asset Management, LLC | $81 260 000 | 2 000 000 | 1,66% | Acciones |
| BRAIDWELL LP | $81 136 688 | 1 996 965 | 1,66% | Acciones |
| MORGAN STANLEY | $79 171 495 | 1 948 597 | 1,62% | Acciones |
| STATE STREET CORP | $74 268 674 | 1 827 927 | 1,52% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $66 749 256 | 2 119 024 | 1,37% | Acciones |
| MPM BIOIMPACT LLC | $65 852 291 | 1 620 780 | 1,35% | Acciones |
| BANK OF AMERICA CORP /DE/ | $63 312 105 | 1 558 260 | 1,30% | Acciones |
| Qube Research & Technologies Ltd | $50 889 359 | 1 252 507 | 1,04% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $46 309 097 | 1 139 726 | 0,95% | Acciones |
| AMERICAN CENTURY COMPANIES INC | $45 793 233 | 1 127 078 | 0,94% | Acciones |
| First Light Asset Management, LLC | $44 496 798 | 1 095 171 | 0,91% | Acciones |
| VICTORY CAPITAL MANAGEMENT INC | $36 683 608 | 902 870 | 0,75% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $31 953 707 | 786 456 | 0,65% | Acciones |
| NORTHERN TRUST CORP | $27 273 701 | 671 270 | 0,56% | Acciones |
| Aberdeen Group plc | $26 325 233 | 647 926 | 0,54% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $25 212 215 | 620 532 | 0,52% | Acciones |
| Tyro Capital Management LLC | $24 904 768 | 612 965 | 0,51% | Acciones |
| GOLDMAN SACHS GROUP INC | $24 356 425 | 599 469 | 0,50% | Acciones |
| Parkman Healthcare Partners LLC | $23 444 973 | 577 036 | 0,48% | Acciones |
| Artisan Partners Limited Partnership | $23 359 203 | 574 925 | 0,48% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $22 276 820 | 548 285 | 0,46% | Acciones |
| NORGES BANK | $20 726 988 | 510 140 | 0,42% | Acciones |
| Opaleye Management Inc. | $20 315 000 | 500 000 | 0,42% | Acciones |
| CITADEL ADVISORS LLC | $19 084 196 | 469 707 | 0,39% | Acciones |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $18 771 060 | 462 000 | 0,38% | Acciones |
| Soleus Capital Management, L.P. | $18 319 620 | 450 889 | 0,38% | Acciones |
| Nuveen, LLC | $16 849 506 | 414 706 | 0,35% | Acciones |
| New Leaf Venture Partners, L.L.C. | $16 709 211 | 1 030 161 | 0,34% | Acciones |
| Sofinnova Investments, Inc. | $15 476 901 | 380 923 | 0,32% | Acciones |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $13 570 989 | 334 014 | 0,28% | Acciones |
| RAYMOND JAMES FINANCIAL INC | $12 902 666 | 317 565 | 0,26% | Acciones |
| Squadron Capital Management LLC | $11 782 700 | 290 000 | 0,24% | Acciones |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $11 511 820 | 283 333 | 0,24% | Acciones |
| DIADEMA PARTNERS LP | $11 060 055 | 272 214 | 0,23% | Acciones |
| PRUDENTIAL FINANCIAL INC | $10 593 257 | 260 725 | 0,22% | Acciones |
Activistas y propietarios del %+ 5 3 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Novo Holdings A/S ×7 presentaciones | 27 de abril de 2026 | 4,90% | Enmienda | · | SEC |
| ORBIMED ADVISORS LLC, ORBIMED CAPITAL GP VI LLC, OrbiMed Genesis GP LLC, ORBIMED CAPITAL LLC ×5 presentaciones | 12 de mayo de 2025 | 14,50% | Enmienda | · | SEC |
| U.S. Venture Partners XI, L.P. (“USVP XI”), Presidio Management Group XI, L.L.C. (“PMG XI”), Casey M. Tansey, Jonathan D. Root ×2 presentaciones | 1 de febrero de 2023 | · | Presentación inicial | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Informantes de la empresa 18 insiders · 7 directivos · 8 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Michael Nofi | Chief Financial Officer | 12 de agosto de 2026 A | · | 0 | 0 | $0 |
| Michael R Carruthers | Chief Financial Officer | 12 de agosto de 2025 A | 86 162 | 0 | 0 | $0 |
| Alan J Russell | Chief Scientific Officer | 12 de agosto de 2026 A | 31 466 | 0 | 6 | $-10 252 060 |
| Behrad Derakhshan | Chief Business Officer | 12 de agosto de 2026 A | 31 826 | 0 | 4 | $-223 420 |
| Joanne M. Donovan | CMO | 12 de agosto de 2026 A | 8 625 | 0 | 11 | $-4 623 076 |
| Robert Blaustein | Chief Development Officer | 12 de agosto de 2025 A | · | 0 | 0 | $0 |
| Marc Semigran | Chief Development Officer | 24 de diciembre de 2024 M | 6 716 | 0 | 0 | $0 |
| Jonathan C Fox | Consejero | 1 de octubre de 2026 A | 25 141 | 1 | 0 | $199 448 |
| Christopher Nathan Martin | Consejero | 5 de junio de 2026 A | · | 0 | 0 | $0 |
| Badreddin Edris | Consejero | 5 de junio de 2026 A | 19 820 | 0 | 5 | $-3 399 467 |
| Laura Brege | Consejero | 5 de junio de 2026 A | · | 0 | 0 | $0 |
| Arlene Morris | Consejero | 5 de junio de 2026 A | · | 0 | 0 | $0 |
| Peter A. Thompson | Consejero | 5 de junio de 2026 A | 443 792 | 0 | 0 | $0 |
| Jonathan D Root | Consejero | 5 de junio de 2026 A | 0 | 0 | 0 | $0 |
| Novo Holdings A/S | Propietario del 10% | 14 de septiembre de 2022 P | 6 071 703 | 0 | 0 | $0 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | Propietario del 10% | 30 de marzo de 2021 C | 681 812 | 0 | 0 | $0 |
| John R Moore | · | 12 de agosto de 2026 A | 17 697 | 0 | 4 | $-219 831 |
| Kevin Koch | · | 12 de agosto de 2026 A | 52 488 | 0 | 3 | $-785 049 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 35 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| IBRN · iShares Trust | 3,53% | 6 153 SH | 11 de septiembre de 2026 | Diario |
| PTH · Invesco Exchange-Traded Fund Trust | 1,36% | 96 973 SH | 2 de octubre de 2026 | Diario |
| PILL · Direxion Shares ETF Trust | 1,33% | 7 137 NS | 31 de julio de 2026 | N-PORT |
| BBC · ETFis Series Trust I | 0,74% | 8 925 NS | 31 de julio de 2026 | N-PORT |
| IHE · iShares Trust | 0,74% | 278 770 SH | 11 de septiembre de 2026 | Diario |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,35% | 35 134 SH | 2 de octubre de 2026 | Diario |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,29% | 7 672 SH | 2 de octubre de 2026 | Diario |
| IBB · iShares Trust | 0,25% | 599 006 SH | 11 de septiembre de 2026 | Diario |
| IWO · iShares Trust | 0,20% | 671 171 SH | 11 de septiembre de 2026 | Diario |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,17% | 76 681 SH | 19 de agosto de 2026 | Diario |
| VFMO · VANGUARD WELLINGTON FUND | 0,13% | 65 171 SH | 19 de agosto de 2026 | Diario |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,13% | 23 462 NS | 31 de julio de 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,11% | 2 494 NS | 31 de julio de 2026 | N-PORT |
| IWM · iShares Trust | 0,10% | 1 832 689 SH | 11 de septiembre de 2026 | Diario |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,09% | 411 642 SH | 19 de agosto de 2026 | Diario |
| RSSL · Global X Funds | 0,09% | 34 242 NS | 31 de julio de 2026 | N-PORT |
| ISCG · iShares Trust | 0,06% | 14 090 SH | 10 de septiembre de 2026 | Diario |
| ESML · iShares Trust | 0,05% | 33 329 SH | 11 de septiembre de 2026 | Diario |
| DFAS · Dimensional ETF Trust | 0,04% | 168 775 NS | 31 de julio de 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,04% | 24 755 SH | 2 de octubre de 2026 | Diario |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 864 416 SH | 19 de agosto de 2026 | Diario |
| VHT · VANGUARD WORLD FUND | 0,03% | 145 298 SH | 19 de agosto de 2026 | Diario |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 22 934 NS | 31 de julio de 2026 | N-PORT |
| WSML · iShares Trust | 0,02% | 3 133 SH | 9 de septiembre de 2026 | Diario |
| TILT · FlexShares Trust | 0,01% | 6 190 NS | 31 de julio de 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,01% | 2 902 915 SH | 19 de agosto de 2026 | Diario |
| DFAC · Dimensional ETF Trust | 0,01% | 103 617 NS | 31 de julio de 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,01% | 5 796 NS | 31 de julio de 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 105 809 SH | 11 de septiembre de 2026 | Diario |
| DFAU · Dimensional ETF Trust | 0,00% | 15 310 NS | 31 de julio de 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 21 128 SH | 10 de septiembre de 2026 | Diario |
| DFUS · Dimensional ETF Trust | 0,00% | 9 509 NS | 31 de julio de 2026 | N-PORT |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 5 890 SH | 19 de agosto de 2026 | Diario |
| ISCB · iShares Trust | · | 3 892 SH | 11 de septiembre de 2026 | Diario |
| ISCV · iShares Trust | · | 9 439 SH | 11 de septiembre de 2026 | Diario |
EWTX Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
calificación · 19 analistas
COMPRA
Objetivo mediano
$53.00
+28,0%
7 36,8%
Compra fuerte
9 47,4%
Compra
3 15,8%
Mantener
0 0,0%
Venta
0 0,0%
Venta fuerte
Precio objetivo a 12 meses
13 analistas · 2026-09-29Objetivo medio $52.62 +27,1%
Ahora
Precio Actual $41.40
Mín$36.00
Media$52.62
Máx$66.00
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| EWTX | $2.64B | -15.2 | · | · | -30.2% | · |
| AMRX | · | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| LGND | $3.74B | 30.8 | 60.4% | 46.4% | 13.5% | · |
| DFTX | $1.32B | -6.5 | 212.0% | · | -71.0% | · |
| MANE | · | · | · | · | 82.6% | · |
| INDV | · | 21.9 | 4.3% | 17.0% | -118.3% | 80.2% |
| OGN | $1.87B | 10.0 | -2.9% | 3.0% | 25.2% | 53.3% |
| AMLX | $1.33B | -7.9 | -77.1% | · | -61.2% | · |
| TARS | $3.48B | -51.5 | 146.7% | -14.7% | -19.7% | · |
| ELVN | $915M | -8.4 | · | · | -21.9% | · |
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Fuente: SEC 10-Q presentada el Ago 6, 2026